[1] |
ROWLEY A H, SHULMAN S T. The epidemiology and pathogenesis of Kawasaki disease[J]. Front Pediatr, 2018, 6:374.
DOI
PMID
|
[2] |
RIFE E, GEDALIA A. Kawasaki disease:an update[J]. Curr Rheumatol Rep, 2020, 22(10):75.
DOI
|
[3] |
JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease(JCS 2013). Digest version[J]. Circ J, 2014, 78(10):2521-2562.
DOI
URL
|
[4] |
NAGATA S. Causes of Kawasaki disease-from past to present[J]. Front Pediatr, 2019, 7:18.
DOI
PMID
|
[5] |
DEL PRINCIPE D, PIETRAFORTE D, GAMBARDELLA L, et al. Pathogenetic determinants in Kawasaki disease:the haematological point of view[J]. J Cell Mol Med, 2017, 21(4):632-639.
DOI
URL
|
[6] |
SWANSON K V, DENG M, TING J P. The NLRP3 inflammasome:molecular activation and regulation to therapeutics[J]. Nat Rev Immunol, 2019, 19(8):477-489.
DOI
|
[7] |
KIM K Y, KIM D S. Recent advances in Kawasaki disease[J]. Yonsei Med J, 2016, 57(1):15-21.
DOI
PMID
|
[8] |
WENG K P, HSIEH K S, HUANG S H, et al. Interleukin-18 and coronary artery lesions in patients with Kawasaki disease[J]. J Chin Med Assoc, 2013, 76(8):438-445.
DOI
URL
|
[9] |
TERAURA H, KOTANI K, MINAMI T, et al. The serum concentration of soluble interleukin-2 receptor in patients with Kawasaki disease[J]. Ann Clin Biochem, 2017, 54(2):209-213.
DOI
PMID
|
[10] |
WU L, CHEN Y, ZHONG S, et al. Blood N-terminal pro-brain natriuretic peptide and interleukin-17 for distinguishing incomplete Kawasaki disease from infectious diseases[J]. Indian Pediatr, 2015, 52(6):477-480.
PMID
|
[11] |
丁艳, 尹薇, 王瑞耕, 等. 川崎病患儿淋巴细胞亚群及免疫球蛋白的变化[J]. 临床儿科杂志, 2016, 34(1):29-32.
|
[12] |
汪希珂, 刘晓英, 吴悦, 等. T细胞免疫及细胞因子在川崎病不同时期表达变化的研究[J]. 贵州医药, 2018, 42(3):276-280.
|
[13] |
祝绚, 王雪梅, 刘成桂, 等. 川崎病患儿外周血淋巴细胞亚群变化及临床意义[J]. 国际检验医学杂志, 2016, 37(10):1393-1395.
|
[14] |
LINDQUIST M E, HICAR M D. B cells and antibodies in Kawasaki disease[J]. Int J Mol Sci, 2019, 20(8):1834.
DOI
URL
|
[15] |
ZHENG X, ZHANG Y, LIU L, et al. N-terminal pro-brain natriuretic peptide as a biomarker for predicting coronary artery lesion of Kawasaki disease[J]. Sci Rep, 2020, 10(1):5130.
DOI
PMID
|
[16] |
DIONNE A, DAHDAH N. A decade of NT-proBNP in acute Kawasaki disease,from physiological response to clinical relevance[J]. Children(Basel), 2018, 5(10):141.
|
[17] |
YANAGISAWA D, AYUSAWA M, KATO M, et al. Factors affecting N-terminal pro-brain natriuretic peptide elevation in the acute phase of Kawasaki disease[J]. Pediatr Int, 2016, 58(11):1105-1111.
DOI
PMID
|